nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—PDGFRA—brain cancer	0.435	1	CbGaD
Pazopanib—UGT1A1—Etoposide—brain cancer	0.0344	0.16	CbGbCtD
Pazopanib—CYP2D6—Lomustine—brain cancer	0.0266	0.124	CbGbCtD
Pazopanib—CYP1A2—Carmustine—brain cancer	0.0263	0.123	CbGbCtD
Pazopanib—ABCG2—Carboplatin—brain cancer	0.0225	0.105	CbGbCtD
Pazopanib—CYP2D6—Hydroxyurea—brain cancer	0.0202	0.094	CbGbCtD
Pazopanib—CYP3A4—Temozolomide—brain cancer	0.0199	0.0927	CbGbCtD
Pazopanib—ABCG2—Etoposide—brain cancer	0.0189	0.0882	CbGbCtD
Pazopanib—CYP3A4—Lomustine—brain cancer	0.0169	0.0788	CbGbCtD
Pazopanib—CYP2C8—Etoposide—brain cancer	0.0101	0.047	CbGbCtD
Pazopanib—CYP1A2—Etoposide—brain cancer	0.0078	0.0364	CbGbCtD
Pazopanib—ABCB1—Etoposide—brain cancer	0.00682	0.0318	CbGbCtD
Pazopanib—CYP3A4—Etoposide—brain cancer	0.00409	0.0191	CbGbCtD
Pazopanib—PLK4—Teniposide—Etoposide—brain cancer	0.00173	1	CbGdCrCtD
Pazopanib—PIP4K2C—telencephalon—brain cancer	0.000491	0.00473	CbGeAlD
Pazopanib—FGFR1—telencephalon—brain cancer	0.000487	0.00469	CbGeAlD
Pazopanib—MAP3K9—brain—brain cancer	0.000483	0.00465	CbGeAlD
Pazopanib—STK36—gonad—brain cancer	0.000474	0.00457	CbGeAlD
Pazopanib—SH2B3—head—brain cancer	0.000471	0.00454	CbGeAlD
Pazopanib—AURKC—endocrine gland—brain cancer	0.000469	0.00452	CbGeAlD
Pazopanib—PI4KB—gonad—brain cancer	0.000467	0.0045	CbGeAlD
Pazopanib—FGFR2—brainstem—brain cancer	0.000467	0.0045	CbGeAlD
Pazopanib—MAP3K2—telencephalon—brain cancer	0.000466	0.00449	CbGeAlD
Pazopanib—AURKC—head—brain cancer	0.000463	0.00447	CbGeAlD
Pazopanib—STK36—pituitary gland—brain cancer	0.000463	0.00446	CbGeAlD
Pazopanib—LIMK2—gonad—brain cancer	0.000459	0.00442	CbGeAlD
Pazopanib—TAOK1—central nervous system—brain cancer	0.000456	0.0044	CbGeAlD
Pazopanib—PI4KB—pituitary gland—brain cancer	0.000456	0.00439	CbGeAlD
Pazopanib—RIOK2—midbrain—brain cancer	0.000454	0.00438	CbGeAlD
Pazopanib—FGFR3—midbrain—brain cancer	0.000454	0.00438	CbGeAlD
Pazopanib—LIMK2—pituitary gland—brain cancer	0.000447	0.00431	CbGeAlD
Pazopanib—STK36—medulla oblongata—brain cancer	0.000447	0.0043	CbGeAlD
Pazopanib—TAOK1—cerebellum—brain cancer	0.000446	0.0043	CbGeAlD
Pazopanib—FGFR3—spinal cord—brain cancer	0.000443	0.00427	CbGeAlD
Pazopanib—RIOK2—spinal cord—brain cancer	0.000443	0.00427	CbGeAlD
Pazopanib—PI4KB—medulla oblongata—brain cancer	0.00044	0.00424	CbGeAlD
Pazopanib—FGF1—telencephalon—brain cancer	0.000439	0.00423	CbGeAlD
Pazopanib—SH2B3—central nervous system—brain cancer	0.00043	0.00414	CbGeAlD
Pazopanib—PLK4—endocrine gland—brain cancer	0.000429	0.00414	CbGeAlD
Pazopanib—AURKC—central nervous system—brain cancer	0.000423	0.00408	CbGeAlD
Pazopanib—SH2B3—cerebellum—brain cancer	0.00042	0.00405	CbGeAlD
Pazopanib—FGFR2—telencephalon—brain cancer	0.000414	0.00399	CbGeAlD
Pazopanib—PIP4K2C—gonad—brain cancer	0.00041	0.00395	CbGeAlD
Pazopanib—TAOK3—brainstem—brain cancer	0.000408	0.00393	CbGeAlD
Pazopanib—STK16—endocrine gland—brain cancer	0.000405	0.00391	CbGeAlD
Pazopanib—PI4KB—midbrain—brain cancer	0.000402	0.00387	CbGeAlD
Pazopanib—LYN—endocrine gland—brain cancer	0.000401	0.00387	CbGeAlD
Pazopanib—STK16—head—brain cancer	0.0004	0.00386	CbGeAlD
Pazopanib—PIP4K2C—pituitary gland—brain cancer	0.0004	0.00385	CbGeAlD
Pazopanib—FGFR3—endocrine gland—brain cancer	0.000399	0.00385	CbGeAlD
Pazopanib—FGFR1—pituitary gland—brain cancer	0.000397	0.00382	CbGeAlD
Pazopanib—LYN—head—brain cancer	0.000396	0.00382	CbGeAlD
Pazopanib—BMPR1B—endocrine gland—brain cancer	0.000395	0.00381	CbGeAlD
Pazopanib—FGFR3—head—brain cancer	0.000394	0.0038	CbGeAlD
Pazopanib—RIOK2—head—brain cancer	0.000394	0.0038	CbGeAlD
Pazopanib—PI4KB—spinal cord—brain cancer	0.000392	0.00378	CbGeAlD
Pazopanib—MAP3K19—head—brain cancer	0.00039	0.00376	CbGeAlD
Pazopanib—BMPR1B—head—brain cancer	0.00039	0.00376	CbGeAlD
Pazopanib—MAP3K2—gonad—brain cancer	0.000389	0.00374	CbGeAlD
Pazopanib—PIP4K2C—medulla oblongata—brain cancer	0.000386	0.00372	CbGeAlD
Pazopanib—LIMK2—spinal cord—brain cancer	0.000385	0.00371	CbGeAlD
Pazopanib—FLT1—telencephalon—brain cancer	0.000384	0.0037	CbGeAlD
Pazopanib—FGFR1—medulla oblongata—brain cancer	0.000383	0.00369	CbGeAlD
Pazopanib—EPHB6—telencephalon—brain cancer	0.00038	0.00366	CbGeAlD
Pazopanib—MAP2K5—brainstem—brain cancer	0.000366	0.00352	CbGeAlD
Pazopanib—STK16—central nervous system—brain cancer	0.000365	0.00352	CbGeAlD
Pazopanib—Haemorrhage—Procarbazine—brain cancer	0.000363	0.00392	CcSEcCtD
Pazopanib—TAOK1—brain—brain cancer	0.000362	0.00349	CbGeAlD
Pazopanib—TAOK3—telencephalon—brain cancer	0.000362	0.00349	CbGeAlD
Pazopanib—LYN—central nervous system—brain cancer	0.000362	0.00348	CbGeAlD
Pazopanib—PDGFRA—telencephalon—brain cancer	0.00036	0.00347	CbGeAlD
Pazopanib—RIOK2—central nervous system—brain cancer	0.00036	0.00347	CbGeAlD
Pazopanib—FGFR3—central nervous system—brain cancer	0.00036	0.00347	CbGeAlD
Pazopanib—STK36—endocrine gland—brain cancer	0.000359	0.00345	CbGeAlD
Pazopanib—FGF1—pituitary gland—brain cancer	0.000357	0.00344	CbGeAlD
Pazopanib—STK16—cerebellum—brain cancer	0.000357	0.00344	CbGeAlD
Pazopanib—BMPR1B—central nervous system—brain cancer	0.000356	0.00343	CbGeAlD
Pazopanib—MAP3K19—central nervous system—brain cancer	0.000356	0.00343	CbGeAlD
Pazopanib—STK36—head—brain cancer	0.000354	0.00341	CbGeAlD
Pazopanib—PI4KB—endocrine gland—brain cancer	0.000353	0.0034	CbGeAlD
Pazopanib—PIP4K2C—midbrain—brain cancer	0.000353	0.0034	CbGeAlD
Pazopanib—Decreased appetite—Lomustine—brain cancer	0.000353	0.00382	CcSEcCtD
Pazopanib—Hepatic failure—Temozolomide—brain cancer	0.000353	0.00381	CcSEcCtD
Pazopanib—FGFR3—cerebellum—brain cancer	0.000352	0.00339	CbGeAlD
Pazopanib—RIOK2—cerebellum—brain cancer	0.000352	0.00339	CbGeAlD
Pazopanib—FGFR1—midbrain—brain cancer	0.00035	0.00337	CbGeAlD
Pazopanib—Phosphatase alkaline increased—Etoposide—brain cancer	0.000349	0.00378	CcSEcCtD
Pazopanib—PI4KB—head—brain cancer	0.000349	0.00336	CbGeAlD
Pazopanib—BMPR1B—cerebellum—brain cancer	0.000348	0.00335	CbGeAlD
Pazopanib—LIMK2—endocrine gland—brain cancer	0.000347	0.00334	CbGeAlD
Pazopanib—FGF1—medulla oblongata—brain cancer	0.000345	0.00332	CbGeAlD
Pazopanib—PIP4K2C—spinal cord—brain cancer	0.000344	0.00332	CbGeAlD
Pazopanib—Pancreatitis—Hydroxyurea—brain cancer	0.000344	0.00372	CcSEcCtD
Pazopanib—LIMK2—head—brain cancer	0.000342	0.0033	CbGeAlD
Pazopanib—FGFR1—spinal cord—brain cancer	0.000341	0.00329	CbGeAlD
Pazopanib—SH2B3—brain—brain cancer	0.000341	0.00329	CbGeAlD
Pazopanib—Hot flush—Temozolomide—brain cancer	0.000339	0.00366	CcSEcCtD
Pazopanib—Flushing—Procarbazine—brain cancer	0.000336	0.00364	CcSEcCtD
Pazopanib—AURKC—brain—brain cancer	0.000336	0.00324	CbGeAlD
Pazopanib—Menopausal symptoms—Temozolomide—brain cancer	0.000336	0.00363	CcSEcCtD
Pazopanib—Skin exfoliation—Etoposide—brain cancer	0.000333	0.00361	CcSEcCtD
Pazopanib—Hyponatraemia—Carmustine—brain cancer	0.000329	0.00356	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Carmustine—brain cancer	0.000328	0.00355	CcSEcCtD
Pazopanib—Neutropenia—Hydroxyurea—brain cancer	0.000328	0.00355	CcSEcCtD
Pazopanib—Chills—Procarbazine—brain cancer	0.000325	0.00352	CcSEcCtD
Pazopanib—MAP2K5—telencephalon—brain cancer	0.000325	0.00313	CbGeAlD
Pazopanib—KIT—brainstem—brain cancer	0.000324	0.00312	CbGeAlD
Pazopanib—STK36—central nervous system—brain cancer	0.000323	0.00311	CbGeAlD
Pazopanib—FLT1—gonad—brain cancer	0.00032	0.00309	CbGeAlD
Pazopanib—Alopecia—Procarbazine—brain cancer	0.00032	0.00347	CcSEcCtD
Pazopanib—PI4KB—central nervous system—brain cancer	0.000318	0.00307	CbGeAlD
Pazopanib—CSF1R—telencephalon—brain cancer	0.000317	0.00305	CbGeAlD
Pazopanib—Face oedema—Carmustine—brain cancer	0.000317	0.00342	CcSEcCtD
Pazopanib—Mouth ulceration—Etoposide—brain cancer	0.000316	0.00342	CcSEcCtD
Pazopanib—STK36—cerebellum—brain cancer	0.000316	0.00304	CbGeAlD
Pazopanib—FGF1—midbrain—brain cancer	0.000315	0.00304	CbGeAlD
Pazopanib—FLT1—pituitary gland—brain cancer	0.000313	0.00301	CbGeAlD
Pazopanib—Infestation—Hydroxyurea—brain cancer	0.000313	0.00338	CcSEcCtD
Pazopanib—Infestation NOS—Hydroxyurea—brain cancer	0.000313	0.00338	CcSEcCtD
Pazopanib—LIMK2—central nervous system—brain cancer	0.000312	0.00301	CbGeAlD
Pazopanib—FLT4—endocrine gland—brain cancer	0.000311	0.003	CbGeAlD
Pazopanib—PI4KB—cerebellum—brain cancer	0.000311	0.003	CbGeAlD
Pazopanib—PIP4K2C—endocrine gland—brain cancer	0.00031	0.00298	CbGeAlD
Pazopanib—EPHB6—pituitary gland—brain cancer	0.000309	0.00298	CbGeAlD
Pazopanib—FLT4—head—brain cancer	0.000307	0.00296	CbGeAlD
Pazopanib—FGF1—spinal cord—brain cancer	0.000307	0.00296	CbGeAlD
Pazopanib—PLK4—brain—brain cancer	0.000307	0.00296	CbGeAlD
Pazopanib—Face oedema—Temozolomide—brain cancer	0.000306	0.00331	CcSEcCtD
Pazopanib—PIP4K2C—head—brain cancer	0.000306	0.00295	CbGeAlD
Pazopanib—LIMK2—cerebellum—brain cancer	0.000305	0.00294	CbGeAlD
Pazopanib—Stomatitis—Hydroxyurea—brain cancer	0.000305	0.0033	CcSEcCtD
Pazopanib—STK10—gonad—brain cancer	0.000303	0.00292	CbGeAlD
Pazopanib—Liver function test abnormal—Carmustine—brain cancer	0.000303	0.00327	CcSEcCtD
Pazopanib—FLT1—medulla oblongata—brain cancer	0.000302	0.00291	CbGeAlD
Pazopanib—PDGFRA—gonad—brain cancer	0.0003	0.00289	CbGeAlD
Pazopanib—EPHB6—medulla oblongata—brain cancer	0.000298	0.00287	CbGeAlD
Pazopanib—Hepatobiliary disease—Hydroxyurea—brain cancer	0.000296	0.0032	CcSEcCtD
Pazopanib—TAOK3—pituitary gland—brain cancer	0.000295	0.00284	CbGeAlD
Pazopanib—Dehydration—Temozolomide—brain cancer	0.000295	0.00319	CcSEcCtD
Pazopanib—MAP3K2—endocrine gland—brain cancer	0.000294	0.00283	CbGeAlD
Pazopanib—Anaemia—Procarbazine—brain cancer	0.000292	0.00316	CcSEcCtD
Pazopanib—Blood alkaline phosphatase increased—Etoposide—brain cancer	0.000291	0.00315	CcSEcCtD
Pazopanib—Dry skin—Temozolomide—brain cancer	0.00029	0.00314	CcSEcCtD
Pazopanib—FGFR2—spinal cord—brain cancer	0.00029	0.0028	CbGeAlD
Pazopanib—STK16—brain—brain cancer	0.00029	0.00279	CbGeAlD
Pazopanib—MAP3K2—head—brain cancer	0.00029	0.00279	CbGeAlD
Pazopanib—KIT—telencephalon—brain cancer	0.000288	0.00277	CbGeAlD
Pazopanib—LYN—brain—brain cancer	0.000287	0.00277	CbGeAlD
Pazopanib—Breast disorder—Temozolomide—brain cancer	0.000286	0.0031	CcSEcCtD
Pazopanib—RIOK2—brain—brain cancer	0.000286	0.00275	CbGeAlD
Pazopanib—FGFR3—brain—brain cancer	0.000286	0.00275	CbGeAlD
Pazopanib—Aspartate aminotransferase increased—Temozolomide—brain cancer	0.000285	0.00309	CcSEcCtD
Pazopanib—TAOK3—medulla oblongata—brain cancer	0.000284	0.00274	CbGeAlD
Pazopanib—Syncope—Procarbazine—brain cancer	0.000283	0.00306	CcSEcCtD
Pazopanib—MAP3K19—brain—brain cancer	0.000283	0.00272	CbGeAlD
Pazopanib—BMPR1B—brain—brain cancer	0.000283	0.00272	CbGeAlD
Pazopanib—Leukopenia—Procarbazine—brain cancer	0.000282	0.00306	CcSEcCtD
Pazopanib—Haemoglobin—Hydroxyurea—brain cancer	0.000282	0.00305	CcSEcCtD
Pazopanib—PDGFRB—telencephalon—brain cancer	0.000281	0.00271	CbGeAlD
Pazopanib—Haemorrhage—Hydroxyurea—brain cancer	0.000281	0.00304	CcSEcCtD
Pazopanib—Cardiac failure congestive—Etoposide—brain cancer	0.00028	0.00302	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Temozolomide—brain cancer	0.000279	0.00302	CcSEcCtD
Pazopanib—PIP4K2C—central nervous system—brain cancer	0.000279	0.00269	CbGeAlD
Pazopanib—Loss of consciousness—Procarbazine—brain cancer	0.000277	0.003	CcSEcCtD
Pazopanib—FGF1—endocrine gland—brain cancer	0.000277	0.00267	CbGeAlD
Pazopanib—FLT1—midbrain—brain cancer	0.000276	0.00266	CbGeAlD
Pazopanib—Abdominal distension—Temozolomide—brain cancer	0.000276	0.00298	CcSEcCtD
Pazopanib—Cough—Procarbazine—brain cancer	0.000275	0.00298	CcSEcCtD
Pazopanib—FGF1—head—brain cancer	0.000273	0.00263	CbGeAlD
Pazopanib—PIP4K2C—cerebellum—brain cancer	0.000273	0.00263	CbGeAlD
Pazopanib—EPHB6—midbrain—brain cancer	0.000273	0.00263	CbGeAlD
Pazopanib—Hypertension—Procarbazine—brain cancer	0.000272	0.00295	CcSEcCtD
Pazopanib—FGFR1—cerebellum—brain cancer	0.000271	0.00261	CbGeAlD
Pazopanib—FLT1—spinal cord—brain cancer	0.000269	0.00259	CbGeAlD
Pazopanib—Myalgia—Procarbazine—brain cancer	0.000269	0.00291	CcSEcCtD
Pazopanib—Arthralgia—Procarbazine—brain cancer	0.000269	0.00291	CcSEcCtD
Pazopanib—EPHB6—spinal cord—brain cancer	0.000266	0.00256	CbGeAlD
Pazopanib—Neutropenia—Carmustine—brain cancer	0.000265	0.00287	CcSEcCtD
Pazopanib—MAP3K2—central nervous system—brain cancer	0.000265	0.00255	CbGeAlD
Pazopanib—CSF1R—gonad—brain cancer	0.000264	0.00255	CbGeAlD
Pazopanib—KDR—pituitary gland—brain cancer	0.000264	0.00255	CbGeAlD
Pazopanib—MAP2K5—pituitary gland—brain cancer	0.000264	0.00255	CbGeAlD
Pazopanib—Dry mouth—Procarbazine—brain cancer	0.000263	0.00284	CcSEcCtD
Pazopanib—FGFR2—endocrine gland—brain cancer	0.000261	0.00252	CbGeAlD
Pazopanib—TAOK3—midbrain—brain cancer	0.00026	0.00251	CbGeAlD
Pazopanib—Cardiac failure—Etoposide—brain cancer	0.00026	0.00281	CcSEcCtD
Pazopanib—MAP3K2—cerebellum—brain cancer	0.000259	0.00249	CbGeAlD
Pazopanib—Vomiting—Lomustine—brain cancer	0.000258	0.00279	CcSEcCtD
Pazopanib—FGFR2—head—brain cancer	0.000258	0.00249	CbGeAlD
Pazopanib—CSF1R—pituitary gland—brain cancer	0.000258	0.00249	CbGeAlD
Pazopanib—Oedema—Procarbazine—brain cancer	0.000258	0.00279	CcSEcCtD
Pazopanib—STK36—brain—brain cancer	0.000256	0.00247	CbGeAlD
Pazopanib—Neutropenia—Temozolomide—brain cancer	0.000256	0.00277	CcSEcCtD
Pazopanib—Infection—Procarbazine—brain cancer	0.000256	0.00277	CcSEcCtD
Pazopanib—KDR—medulla oblongata—brain cancer	0.000255	0.00246	CbGeAlD
Pazopanib—MAP2K5—medulla oblongata—brain cancer	0.000255	0.00246	CbGeAlD
Pazopanib—Angiopathy—Hydroxyurea—brain cancer	0.000255	0.00275	CcSEcCtD
Pazopanib—TAOK3—spinal cord—brain cancer	0.000254	0.00244	CbGeAlD
Pazopanib—Shock—Procarbazine—brain cancer	0.000253	0.00274	CcSEcCtD
Pazopanib—PI4KB—brain—brain cancer	0.000253	0.00243	CbGeAlD
Pazopanib—Thrombocytopenia—Procarbazine—brain cancer	0.000252	0.00273	CcSEcCtD
Pazopanib—PDGFRA—spinal cord—brain cancer	0.000252	0.00243	CbGeAlD
Pazopanib—Chills—Hydroxyurea—brain cancer	0.000252	0.00272	CcSEcCtD
Pazopanib—Photosensitivity reaction—Temozolomide—brain cancer	0.00025	0.0027	CcSEcCtD
Pazopanib—FGF1—central nervous system—brain cancer	0.000249	0.0024	CbGeAlD
Pazopanib—Hyperhidrosis—Procarbazine—brain cancer	0.000249	0.00269	CcSEcCtD
Pazopanib—CSF1R—medulla oblongata—brain cancer	0.000249	0.0024	CbGeAlD
Pazopanib—LIMK2—brain—brain cancer	0.000248	0.00239	CbGeAlD
Pazopanib—Alopecia—Hydroxyurea—brain cancer	0.000248	0.00268	CcSEcCtD
Pazopanib—Weight decreased—Temozolomide—brain cancer	0.000248	0.00268	CcSEcCtD
Pazopanib—Stomatitis—Carmustine—brain cancer	0.000246	0.00266	CcSEcCtD
Pazopanib—Anorexia—Procarbazine—brain cancer	0.000246	0.00266	CcSEcCtD
Pazopanib—Erythema—Hydroxyurea—brain cancer	0.000244	0.00264	CcSEcCtD
Pazopanib—Infestation—Temozolomide—brain cancer	0.000244	0.00264	CcSEcCtD
Pazopanib—Infestation NOS—Temozolomide—brain cancer	0.000244	0.00264	CcSEcCtD
Pazopanib—FGF1—cerebellum—brain cancer	0.000244	0.00235	CbGeAlD
Pazopanib—FLT1—endocrine gland—brain cancer	0.000242	0.00233	CbGeAlD
Pazopanib—Nausea—Lomustine—brain cancer	0.000241	0.00261	CcSEcCtD
Pazopanib—KIT—gonad—brain cancer	0.00024	0.00231	CbGeAlD
Pazopanib—FLT1—head—brain cancer	0.000239	0.0023	CbGeAlD
Pazopanib—Stomatitis—Temozolomide—brain cancer	0.000238	0.00257	CcSEcCtD
Pazopanib—EPHB6—head—brain cancer	0.000236	0.00228	CbGeAlD
Pazopanib—FGFR2—central nervous system—brain cancer	0.000235	0.00227	CbGeAlD
Pazopanib—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000235	0.00254	CcSEcCtD
Pazopanib—PDGFRB—gonad—brain cancer	0.000234	0.00226	CbGeAlD
Pazopanib—KIT—pituitary gland—brain cancer	0.000234	0.00226	CbGeAlD
Pazopanib—KDR—midbrain—brain cancer	0.000233	0.00225	CbGeAlD
Pazopanib—MAP2K5—midbrain—brain cancer	0.000233	0.00225	CbGeAlD
Pazopanib—Insomnia—Procarbazine—brain cancer	0.000233	0.00252	CcSEcCtD
Pazopanib—Paraesthesia—Procarbazine—brain cancer	0.000231	0.0025	CcSEcCtD
Pazopanib—Hepatobiliary disease—Temozolomide—brain cancer	0.000231	0.0025	CcSEcCtD
Pazopanib—FGFR2—cerebellum—brain cancer	0.00023	0.00222	CbGeAlD
Pazopanib—STK10—endocrine gland—brain cancer	0.000229	0.00221	CbGeAlD
Pazopanib—Somnolence—Procarbazine—brain cancer	0.000229	0.00248	CcSEcCtD
Pazopanib—PDGFRB—pituitary gland—brain cancer	0.000229	0.0022	CbGeAlD
Pazopanib—TAOK3—endocrine gland—brain cancer	0.000228	0.0022	CbGeAlD
Pazopanib—Haemoglobin—Carmustine—brain cancer	0.000228	0.00247	CcSEcCtD
Pazopanib—CSF1R—midbrain—brain cancer	0.000227	0.00219	CbGeAlD
Pazopanib—KDR—spinal cord—brain cancer	0.000227	0.00219	CbGeAlD
Pazopanib—MAP2K5—spinal cord—brain cancer	0.000227	0.00219	CbGeAlD
Pazopanib—PDGFRA—endocrine gland—brain cancer	0.000227	0.00219	CbGeAlD
Pazopanib—Haemorrhage—Carmustine—brain cancer	0.000227	0.00245	CcSEcCtD
Pazopanib—STK10—head—brain cancer	0.000226	0.00218	CbGeAlD
Pazopanib—KIT—medulla oblongata—brain cancer	0.000226	0.00218	CbGeAlD
Pazopanib—Anaemia—Hydroxyurea—brain cancer	0.000226	0.00244	CcSEcCtD
Pazopanib—Hypoaesthesia—Carmustine—brain cancer	0.000226	0.00244	CcSEcCtD
Pazopanib—TAOK3—head—brain cancer	0.000225	0.00217	CbGeAlD
Pazopanib—PDGFRA—head—brain cancer	0.000224	0.00216	CbGeAlD
Pazopanib—Decreased appetite—Procarbazine—brain cancer	0.000224	0.00242	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Etoposide—brain cancer	0.000224	0.00242	CcSEcCtD
Pazopanib—Oedema peripheral—Carmustine—brain cancer	0.000223	0.00242	CcSEcCtD
Pazopanib—Connective tissue disorder—Carmustine—brain cancer	0.000223	0.00241	CcSEcCtD
Pazopanib—FLT4—brain—brain cancer	0.000223	0.00215	CbGeAlD
Pazopanib—Fatigue—Procarbazine—brain cancer	0.000222	0.0024	CcSEcCtD
Pazopanib—CSF1R—spinal cord—brain cancer	0.000222	0.00214	CbGeAlD
Pazopanib—PIP4K2C—brain—brain cancer	0.000222	0.00214	CbGeAlD
Pazopanib—PDGFRB—medulla oblongata—brain cancer	0.000221	0.00213	CbGeAlD
Pazopanib—Haemoglobin—Temozolomide—brain cancer	0.00022	0.00238	CcSEcCtD
Pazopanib—Pain—Procarbazine—brain cancer	0.00022	0.00238	CcSEcCtD
Pazopanib—FGFR1—brain—brain cancer	0.00022	0.00212	CbGeAlD
Pazopanib—Haemorrhage—Temozolomide—brain cancer	0.000219	0.00237	CcSEcCtD
Pazopanib—Leukopenia—Hydroxyurea—brain cancer	0.000219	0.00237	CcSEcCtD
Pazopanib—FLT1—central nervous system—brain cancer	0.000218	0.0021	CbGeAlD
Pazopanib—Hypoaesthesia—Temozolomide—brain cancer	0.000218	0.00236	CcSEcCtD
Pazopanib—UGT1A1—endocrine gland—brain cancer	0.000216	0.00209	CbGeAlD
Pazopanib—Urinary tract disorder—Temozolomide—brain cancer	0.000216	0.00234	CcSEcCtD
Pazopanib—Oedema peripheral—Temozolomide—brain cancer	0.000216	0.00234	CcSEcCtD
Pazopanib—EPHB6—central nervous system—brain cancer	0.000216	0.00208	CbGeAlD
Pazopanib—Connective tissue disorder—Temozolomide—brain cancer	0.000215	0.00233	CcSEcCtD
Pazopanib—Urethral disorder—Temozolomide—brain cancer	0.000215	0.00232	CcSEcCtD
Pazopanib—FLT1—cerebellum—brain cancer	0.000213	0.00206	CbGeAlD
Pazopanib—CYP2D6—hindbrain—brain cancer	0.000213	0.00205	CbGeAlD
Pazopanib—Eye disorder—Carmustine—brain cancer	0.000212	0.00229	CcSEcCtD
Pazopanib—EPHB6—cerebellum—brain cancer	0.000211	0.00203	CbGeAlD
Pazopanib—Gastrointestinal pain—Procarbazine—brain cancer	0.000211	0.00228	CcSEcCtD
Pazopanib—Flushing—Carmustine—brain cancer	0.00021	0.00228	CcSEcCtD
Pazopanib—MAP3K2—brain—brain cancer	0.00021	0.00202	CbGeAlD
Pazopanib—STK10—central nervous system—brain cancer	0.000207	0.00199	CbGeAlD
Pazopanib—KIT—midbrain—brain cancer	0.000207	0.00199	CbGeAlD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000207	0.00223	CcSEcCtD
Pazopanib—TAOK3—central nervous system—brain cancer	0.000206	0.00198	CbGeAlD
Pazopanib—Neutropenia—Etoposide—brain cancer	0.000205	0.00222	CcSEcCtD
Pazopanib—Eye disorder—Temozolomide—brain cancer	0.000205	0.00222	CcSEcCtD
Pazopanib—KDR—endocrine gland—brain cancer	0.000205	0.00197	CbGeAlD
Pazopanib—MAP2K5—endocrine gland—brain cancer	0.000205	0.00197	CbGeAlD
Pazopanib—PDGFRA—central nervous system—brain cancer	0.000204	0.00197	CbGeAlD
Pazopanib—Abdominal pain—Procarbazine—brain cancer	0.000204	0.0022	CcSEcCtD
Pazopanib—Flushing—Temozolomide—brain cancer	0.000203	0.0022	CcSEcCtD
Pazopanib—Cardiac disorder—Temozolomide—brain cancer	0.000203	0.0022	CcSEcCtD
Pazopanib—MAP2K5—head—brain cancer	0.000202	0.00195	CbGeAlD
Pazopanib—KDR—head—brain cancer	0.000202	0.00195	CbGeAlD
Pazopanib—STK10—cerebellum—brain cancer	0.000202	0.00195	CbGeAlD
Pazopanib—PDGFRB—midbrain—brain cancer	0.000202	0.00194	CbGeAlD
Pazopanib—KIT—spinal cord—brain cancer	0.000202	0.00194	CbGeAlD
Pazopanib—TAOK3—cerebellum—brain cancer	0.000201	0.00194	CbGeAlD
Pazopanib—Alopecia—Carmustine—brain cancer	0.0002	0.00217	CcSEcCtD
Pazopanib—PDGFRA—cerebellum—brain cancer	0.0002	0.00193	CbGeAlD
Pazopanib—CSF1R—endocrine gland—brain cancer	0.0002	0.00193	CbGeAlD
Pazopanib—Oedema—Hydroxyurea—brain cancer	0.000199	0.00216	CcSEcCtD
Pazopanib—Angiopathy—Temozolomide—brain cancer	0.000199	0.00215	CcSEcCtD
Pazopanib—Mental disorder—Carmustine—brain cancer	0.000199	0.00215	CcSEcCtD
Pazopanib—Infection—Hydroxyurea—brain cancer	0.000198	0.00214	CcSEcCtD
Pazopanib—FGF1—brain—brain cancer	0.000198	0.00191	CbGeAlD
Pazopanib—Mediastinal disorder—Temozolomide—brain cancer	0.000198	0.00214	CcSEcCtD
Pazopanib—Erythema—Carmustine—brain cancer	0.000197	0.00214	CcSEcCtD
Pazopanib—Malnutrition—Carmustine—brain cancer	0.000197	0.00214	CcSEcCtD
Pazopanib—CSF1R—head—brain cancer	0.000197	0.0019	CbGeAlD
Pazopanib—PDGFRB—spinal cord—brain cancer	0.000197	0.0019	CbGeAlD
Pazopanib—Chills—Temozolomide—brain cancer	0.000197	0.00213	CcSEcCtD
Pazopanib—Nervous system disorder—Hydroxyurea—brain cancer	0.000195	0.00211	CcSEcCtD
Pazopanib—Infestation—Etoposide—brain cancer	0.000195	0.00211	CcSEcCtD
Pazopanib—Infestation NOS—Etoposide—brain cancer	0.000195	0.00211	CcSEcCtD
Pazopanib—Thrombocytopenia—Hydroxyurea—brain cancer	0.000195	0.00211	CcSEcCtD
Pazopanib—Alopecia—Temozolomide—brain cancer	0.000194	0.0021	CcSEcCtD
Pazopanib—Skin disorder—Hydroxyurea—brain cancer	0.000194	0.00209	CcSEcCtD
Pazopanib—Acute coronary syndrome—Etoposide—brain cancer	0.000193	0.00208	CcSEcCtD
Pazopanib—Mental disorder—Temozolomide—brain cancer	0.000192	0.00208	CcSEcCtD
Pazopanib—Myocardial infarction—Etoposide—brain cancer	0.000192	0.00207	CcSEcCtD
Pazopanib—Erythema—Temozolomide—brain cancer	0.000191	0.00206	CcSEcCtD
Pazopanib—Malnutrition—Temozolomide—brain cancer	0.000191	0.00206	CcSEcCtD
Pazopanib—Jaundice—Etoposide—brain cancer	0.00019	0.00206	CcSEcCtD
Pazopanib—Stomatitis—Etoposide—brain cancer	0.00019	0.00206	CcSEcCtD
Pazopanib—Anorexia—Hydroxyurea—brain cancer	0.00019	0.00206	CcSEcCtD
Pazopanib—FGFR2—brain—brain cancer	0.000187	0.0018	CbGeAlD
Pazopanib—Dysgeusia—Temozolomide—brain cancer	0.000187	0.00202	CcSEcCtD
Pazopanib—Vision blurred—Carmustine—brain cancer	0.000186	0.00201	CcSEcCtD
Pazopanib—Asthenia—Procarbazine—brain cancer	0.000185	0.002	CcSEcCtD
Pazopanib—Hepatobiliary disease—Etoposide—brain cancer	0.000185	0.002	CcSEcCtD
Pazopanib—KDR—central nervous system—brain cancer	0.000184	0.00178	CbGeAlD
Pazopanib—MAP2K5—central nervous system—brain cancer	0.000184	0.00178	CbGeAlD
Pazopanib—Anaemia—Carmustine—brain cancer	0.000182	0.00197	CcSEcCtD
Pazopanib—Pruritus—Procarbazine—brain cancer	0.000182	0.00197	CcSEcCtD
Pazopanib—KIT—endocrine gland—brain cancer	0.000181	0.00175	CbGeAlD
Pazopanib—KDR—cerebellum—brain cancer	0.00018	0.00174	CbGeAlD
Pazopanib—MAP2K5—cerebellum—brain cancer	0.00018	0.00174	CbGeAlD
Pazopanib—SLCO1B1—endocrine gland—brain cancer	0.00018	0.00174	CbGeAlD
Pazopanib—CSF1R—central nervous system—brain cancer	0.00018	0.00173	CbGeAlD
Pazopanib—Vision blurred—Temozolomide—brain cancer	0.00018	0.00195	CcSEcCtD
Pazopanib—KIT—head—brain cancer	0.000179	0.00173	CbGeAlD
Pazopanib—Dyspnoea—Hydroxyurea—brain cancer	0.000178	0.00192	CcSEcCtD
Pazopanib—Somnolence—Hydroxyurea—brain cancer	0.000177	0.00192	CcSEcCtD
Pazopanib—PDGFRB—endocrine gland—brain cancer	0.000177	0.00171	CbGeAlD
Pazopanib—Leukopenia—Carmustine—brain cancer	0.000177	0.00191	CcSEcCtD
Pazopanib—Anaemia—Temozolomide—brain cancer	0.000176	0.00191	CcSEcCtD
Pazopanib—Diarrhoea—Procarbazine—brain cancer	0.000176	0.00191	CcSEcCtD
Pazopanib—CSF1R—cerebellum—brain cancer	0.000176	0.0017	CbGeAlD
Pazopanib—Dyspepsia—Hydroxyurea—brain cancer	0.000175	0.0019	CcSEcCtD
Pazopanib—PDGFRB—head—brain cancer	0.000175	0.00169	CbGeAlD
Pazopanib—Hypoaesthesia—Etoposide—brain cancer	0.000175	0.00189	CcSEcCtD
Pazopanib—Decreased appetite—Hydroxyurea—brain cancer	0.000173	0.00187	CcSEcCtD
Pazopanib—FLT1—brain—brain cancer	0.000173	0.00167	CbGeAlD
Pazopanib—Urinary tract disorder—Etoposide—brain cancer	0.000173	0.00187	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000172	0.00186	CcSEcCtD
Pazopanib—Urethral disorder—Etoposide—brain cancer	0.000172	0.00186	CcSEcCtD
Pazopanib—Fatigue—Hydroxyurea—brain cancer	0.000172	0.00186	CcSEcCtD
Pazopanib—EPHB6—brain—brain cancer	0.000171	0.00165	CbGeAlD
Pazopanib—Leukopenia—Temozolomide—brain cancer	0.000171	0.00185	CcSEcCtD
Pazopanib—Hypertension—Carmustine—brain cancer	0.00017	0.00184	CcSEcCtD
Pazopanib—Pain—Hydroxyurea—brain cancer	0.00017	0.00184	CcSEcCtD
Pazopanib—Dizziness—Procarbazine—brain cancer	0.00017	0.00184	CcSEcCtD
Pazopanib—Myalgia—Carmustine—brain cancer	0.000168	0.00182	CcSEcCtD
Pazopanib—Chest pain—Carmustine—brain cancer	0.000168	0.00182	CcSEcCtD
Pazopanib—Cough—Temozolomide—brain cancer	0.000166	0.0018	CcSEcCtD
Pazopanib—Hypertension—Temozolomide—brain cancer	0.000165	0.00178	CcSEcCtD
Pazopanib—STK10—brain—brain cancer	0.000164	0.00158	CbGeAlD
Pazopanib—Eye disorder—Etoposide—brain cancer	0.000164	0.00177	CcSEcCtD
Pazopanib—Vomiting—Procarbazine—brain cancer	0.000164	0.00177	CcSEcCtD
Pazopanib—KIT—central nervous system—brain cancer	0.000163	0.00158	CbGeAlD
Pazopanib—TAOK3—brain—brain cancer	0.000163	0.00157	CbGeAlD
Pazopanib—Flushing—Etoposide—brain cancer	0.000163	0.00176	CcSEcCtD
Pazopanib—Cardiac disorder—Etoposide—brain cancer	0.000163	0.00176	CcSEcCtD
Pazopanib—Myalgia—Temozolomide—brain cancer	0.000162	0.00176	CcSEcCtD
Pazopanib—Arthralgia—Temozolomide—brain cancer	0.000162	0.00176	CcSEcCtD
Pazopanib—Rash—Procarbazine—brain cancer	0.000162	0.00176	CcSEcCtD
Pazopanib—PDGFRA—brain—brain cancer	0.000162	0.00156	CbGeAlD
Pazopanib—Dermatitis—Procarbazine—brain cancer	0.000162	0.00176	CcSEcCtD
Pazopanib—Headache—Procarbazine—brain cancer	0.000161	0.00175	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000161	0.00175	CcSEcCtD
Pazopanib—Oedema—Carmustine—brain cancer	0.000161	0.00174	CcSEcCtD
Pazopanib—ABCB1—blood vessel—brain cancer	0.00016	0.00155	CbGeAlD
Pazopanib—Infection—Carmustine—brain cancer	0.00016	0.00173	CcSEcCtD
Pazopanib—KIT—cerebellum—brain cancer	0.00016	0.00154	CbGeAlD
Pazopanib—PDGFRB—central nervous system—brain cancer	0.00016	0.00154	CbGeAlD
Pazopanib—Angiopathy—Etoposide—brain cancer	0.000159	0.00172	CcSEcCtD
Pazopanib—Dry mouth—Temozolomide—brain cancer	0.000159	0.00172	CcSEcCtD
Pazopanib—Mediastinal disorder—Etoposide—brain cancer	0.000158	0.00171	CcSEcCtD
Pazopanib—ABCG2—telencephalon—brain cancer	0.000158	0.00152	CbGeAlD
Pazopanib—Thrombocytopenia—Carmustine—brain cancer	0.000158	0.00171	CcSEcCtD
Pazopanib—Chills—Etoposide—brain cancer	0.000157	0.0017	CcSEcCtD
Pazopanib—PDGFRB—cerebellum—brain cancer	0.000156	0.0015	CbGeAlD
Pazopanib—Oedema—Temozolomide—brain cancer	0.000156	0.00168	CcSEcCtD
Pazopanib—Alopecia—Etoposide—brain cancer	0.000155	0.00168	CcSEcCtD
Pazopanib—Infection—Temozolomide—brain cancer	0.000155	0.00167	CcSEcCtD
Pazopanib—Anorexia—Carmustine—brain cancer	0.000154	0.00166	CcSEcCtD
Pazopanib—Nausea—Procarbazine—brain cancer	0.000153	0.00166	CcSEcCtD
Pazopanib—Nervous system disorder—Temozolomide—brain cancer	0.000153	0.00165	CcSEcCtD
Pazopanib—Thrombocytopenia—Temozolomide—brain cancer	0.000152	0.00165	CcSEcCtD
Pazopanib—Skin disorder—Temozolomide—brain cancer	0.000151	0.00164	CcSEcCtD
Pazopanib—Hyperhidrosis—Temozolomide—brain cancer	0.000151	0.00163	CcSEcCtD
Pazopanib—Dysgeusia—Etoposide—brain cancer	0.00015	0.00162	CcSEcCtD
Pazopanib—Anorexia—Temozolomide—brain cancer	0.000148	0.00161	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Carmustine—brain cancer	0.000147	0.00159	CcSEcCtD
Pazopanib—Muscle spasms—Etoposide—brain cancer	0.000147	0.00159	CcSEcCtD
Pazopanib—MAP2K5—brain—brain cancer	0.000146	0.00141	CbGeAlD
Pazopanib—KDR—brain—brain cancer	0.000146	0.00141	CbGeAlD
Pazopanib—Insomnia—Carmustine—brain cancer	0.000146	0.00158	CcSEcCtD
Pazopanib—Paraesthesia—Carmustine—brain cancer	0.000145	0.00157	CcSEcCtD
Pazopanib—Dyspnoea—Carmustine—brain cancer	0.000144	0.00155	CcSEcCtD
Pazopanib—Somnolence—Carmustine—brain cancer	0.000143	0.00155	CcSEcCtD
Pazopanib—Asthenia—Hydroxyurea—brain cancer	0.000143	0.00155	CcSEcCtD
Pazopanib—CSF1R—brain—brain cancer	0.000143	0.00138	CbGeAlD
Pazopanib—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000142	0.00153	CcSEcCtD
Pazopanib—Anaemia—Etoposide—brain cancer	0.000141	0.00153	CcSEcCtD
Pazopanib—Insomnia—Temozolomide—brain cancer	0.000141	0.00152	CcSEcCtD
Pazopanib—Decreased appetite—Carmustine—brain cancer	0.00014	0.00152	CcSEcCtD
Pazopanib—Paraesthesia—Temozolomide—brain cancer	0.00014	0.00151	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Carmustine—brain cancer	0.000139	0.00151	CcSEcCtD
Pazopanib—Dyspnoea—Temozolomide—brain cancer	0.000139	0.0015	CcSEcCtD
Pazopanib—Somnolence—Temozolomide—brain cancer	0.000138	0.0015	CcSEcCtD
Pazopanib—Pain—Carmustine—brain cancer	0.000138	0.00149	CcSEcCtD
Pazopanib—Dyspepsia—Temozolomide—brain cancer	0.000137	0.00148	CcSEcCtD
Pazopanib—Leukopenia—Etoposide—brain cancer	0.000137	0.00148	CcSEcCtD
Pazopanib—Diarrhoea—Hydroxyurea—brain cancer	0.000136	0.00148	CcSEcCtD
Pazopanib—Decreased appetite—Temozolomide—brain cancer	0.000135	0.00146	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Temozolomide—brain cancer	0.000134	0.00145	CcSEcCtD
Pazopanib—Fatigue—Temozolomide—brain cancer	0.000134	0.00145	CcSEcCtD
Pazopanib—Loss of consciousness—Etoposide—brain cancer	0.000134	0.00145	CcSEcCtD
Pazopanib—Cough—Etoposide—brain cancer	0.000133	0.00144	CcSEcCtD
Pazopanib—Pain—Temozolomide—brain cancer	0.000133	0.00144	CcSEcCtD
Pazopanib—CYP2C8—pituitary gland—brain cancer	0.000132	0.00127	CbGeAlD
Pazopanib—Hypertension—Etoposide—brain cancer	0.000132	0.00143	CcSEcCtD
Pazopanib—Dizziness—Hydroxyurea—brain cancer	0.000132	0.00143	CcSEcCtD
Pazopanib—Gastrointestinal pain—Carmustine—brain cancer	0.000132	0.00143	CcSEcCtD
Pazopanib—Chest pain—Etoposide—brain cancer	0.00013	0.00141	CcSEcCtD
Pazopanib—KIT—brain—brain cancer	0.00013	0.00125	CbGeAlD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000129	0.0014	CcSEcCtD
Pazopanib—ABCG2—pituitary gland—brain cancer	0.000129	0.00124	CbGeAlD
Pazopanib—Abdominal pain—Carmustine—brain cancer	0.000127	0.00138	CcSEcCtD
Pazopanib—Gastrointestinal pain—Temozolomide—brain cancer	0.000127	0.00138	CcSEcCtD
Pazopanib—PDGFRB—brain—brain cancer	0.000127	0.00122	CbGeAlD
Pazopanib—Vomiting—Hydroxyurea—brain cancer	0.000127	0.00137	CcSEcCtD
Pazopanib—Rash—Hydroxyurea—brain cancer	0.000126	0.00136	CcSEcCtD
Pazopanib—Dermatitis—Hydroxyurea—brain cancer	0.000126	0.00136	CcSEcCtD
Pazopanib—Headache—Hydroxyurea—brain cancer	0.000125	0.00135	CcSEcCtD
Pazopanib—ABCG2—medulla oblongata—brain cancer	0.000124	0.0012	CbGeAlD
Pazopanib—Infection—Etoposide—brain cancer	0.000124	0.00134	CcSEcCtD
Pazopanib—Abdominal pain—Temozolomide—brain cancer	0.000123	0.00133	CcSEcCtD
Pazopanib—Thrombocytopenia—Etoposide—brain cancer	0.000122	0.00132	CcSEcCtD
Pazopanib—CYP2D6—brainstem—brain cancer	0.000122	0.00118	CbGeAlD
Pazopanib—Skin disorder—Etoposide—brain cancer	0.000121	0.00131	CcSEcCtD
Pazopanib—Hyperhidrosis—Etoposide—brain cancer	0.00012	0.0013	CcSEcCtD
Pazopanib—Anorexia—Etoposide—brain cancer	0.000119	0.00129	CcSEcCtD
Pazopanib—Nausea—Hydroxyurea—brain cancer	0.000118	0.00128	CcSEcCtD
Pazopanib—Asthenia—Carmustine—brain cancer	0.000116	0.00125	CcSEcCtD
Pazopanib—ABCG2—midbrain—brain cancer	0.000113	0.00109	CbGeAlD
Pazopanib—Paraesthesia—Etoposide—brain cancer	0.000112	0.00121	CcSEcCtD
Pazopanib—Asthenia—Temozolomide—brain cancer	0.000112	0.00121	CcSEcCtD
Pazopanib—Dyspnoea—Etoposide—brain cancer	0.000111	0.0012	CcSEcCtD
Pazopanib—Somnolence—Etoposide—brain cancer	0.000111	0.0012	CcSEcCtD
Pazopanib—ABCG2—spinal cord—brain cancer	0.000111	0.00107	CbGeAlD
Pazopanib—Diarrhoea—Carmustine—brain cancer	0.00011	0.00119	CcSEcCtD
Pazopanib—Pruritus—Temozolomide—brain cancer	0.00011	0.00119	CcSEcCtD
Pazopanib—Decreased appetite—Etoposide—brain cancer	0.000108	0.00117	CcSEcCtD
Pazopanib—CYP2D6—telencephalon—brain cancer	0.000108	0.00104	CbGeAlD
Pazopanib—Gastrointestinal disorder—Etoposide—brain cancer	0.000108	0.00116	CcSEcCtD
Pazopanib—Fatigue—Etoposide—brain cancer	0.000107	0.00116	CcSEcCtD
Pazopanib—Dizziness—Carmustine—brain cancer	0.000107	0.00115	CcSEcCtD
Pazopanib—Pain—Etoposide—brain cancer	0.000107	0.00115	CcSEcCtD
Pazopanib—Diarrhoea—Temozolomide—brain cancer	0.000107	0.00115	CcSEcCtD
Pazopanib—Dizziness—Temozolomide—brain cancer	0.000103	0.00111	CcSEcCtD
Pazopanib—Vomiting—Carmustine—brain cancer	0.000102	0.00111	CcSEcCtD
Pazopanib—CYP2C8—endocrine gland—brain cancer	0.000102	0.000987	CbGeAlD
Pazopanib—Gastrointestinal pain—Etoposide—brain cancer	0.000102	0.0011	CcSEcCtD
Pazopanib—Rash—Carmustine—brain cancer	0.000102	0.0011	CcSEcCtD
Pazopanib—Dermatitis—Carmustine—brain cancer	0.000102	0.0011	CcSEcCtD
Pazopanib—Headache—Carmustine—brain cancer	0.000101	0.00109	CcSEcCtD
Pazopanib—Vomiting—Temozolomide—brain cancer	9.9e-05	0.00107	CcSEcCtD
Pazopanib—Abdominal pain—Etoposide—brain cancer	9.85e-05	0.00107	CcSEcCtD
Pazopanib—Rash—Temozolomide—brain cancer	9.82e-05	0.00106	CcSEcCtD
Pazopanib—Dermatitis—Temozolomide—brain cancer	9.81e-05	0.00106	CcSEcCtD
Pazopanib—Headache—Temozolomide—brain cancer	9.76e-05	0.00106	CcSEcCtD
Pazopanib—CYP1A2—endocrine gland—brain cancer	9.58e-05	0.000924	CbGeAlD
Pazopanib—Nausea—Carmustine—brain cancer	9.57e-05	0.00104	CcSEcCtD
Pazopanib—Nausea—Temozolomide—brain cancer	9.25e-05	0.001	CcSEcCtD
Pazopanib—Asthenia—Etoposide—brain cancer	8.94e-05	0.000967	CcSEcCtD
Pazopanib—Pruritus—Etoposide—brain cancer	8.82e-05	0.000954	CcSEcCtD
Pazopanib—ABCG2—cerebellum—brain cancer	8.77e-05	0.000845	CbGeAlD
Pazopanib—Diarrhoea—Etoposide—brain cancer	8.53e-05	0.000922	CcSEcCtD
Pazopanib—Dizziness—Etoposide—brain cancer	8.24e-05	0.000891	CcSEcCtD
Pazopanib—Vomiting—Etoposide—brain cancer	7.92e-05	0.000857	CcSEcCtD
Pazopanib—Rash—Etoposide—brain cancer	7.86e-05	0.00085	CcSEcCtD
Pazopanib—Dermatitis—Etoposide—brain cancer	7.85e-05	0.000849	CcSEcCtD
Pazopanib—Headache—Etoposide—brain cancer	7.81e-05	0.000845	CcSEcCtD
Pazopanib—ABCB1—telencephalon—brain cancer	7.79e-05	0.00075	CbGeAlD
Pazopanib—Nausea—Etoposide—brain cancer	7.4e-05	0.000801	CcSEcCtD
Pazopanib—CYP2C8—brain—brain cancer	7.33e-05	0.000706	CbGeAlD
Pazopanib—ABCG2—brain—brain cancer	7.12e-05	0.000687	CbGeAlD
Pazopanib—CYP3A4—endocrine gland—brain cancer	6.94e-05	0.000669	CbGeAlD
Pazopanib—CYP2D6—endocrine gland—brain cancer	6.83e-05	0.000658	CbGeAlD
Pazopanib—CYP2D6—head—brain cancer	6.74e-05	0.000649	CbGeAlD
Pazopanib—ABCB1—gonad—brain cancer	6.5e-05	0.000626	CbGeAlD
Pazopanib—ABCB1—pituitary gland—brain cancer	6.34e-05	0.000611	CbGeAlD
Pazopanib—CYP3A4—central nervous system—brain cancer	6.25e-05	0.000602	CbGeAlD
Pazopanib—CYP2D6—central nervous system—brain cancer	6.15e-05	0.000593	CbGeAlD
Pazopanib—ABCB1—medulla oblongata—brain cancer	6.12e-05	0.000589	CbGeAlD
Pazopanib—CYP2D6—cerebellum—brain cancer	6.01e-05	0.000579	CbGeAlD
Pazopanib—ABCB1—midbrain—brain cancer	5.59e-05	0.000539	CbGeAlD
Pazopanib—ABCB1—spinal cord—brain cancer	5.45e-05	0.000526	CbGeAlD
Pazopanib—ABCB1—endocrine gland—brain cancer	4.91e-05	0.000473	CbGeAlD
Pazopanib—CYP2D6—brain—brain cancer	4.88e-05	0.000471	CbGeAlD
Pazopanib—ABCB1—head—brain cancer	4.85e-05	0.000467	CbGeAlD
Pazopanib—ABCB1—central nervous system—brain cancer	4.43e-05	0.000426	CbGeAlD
Pazopanib—ABCB1—cerebellum—brain cancer	4.33e-05	0.000417	CbGeAlD
Pazopanib—ABCB1—brain—brain cancer	3.51e-05	0.000339	CbGeAlD
Pazopanib—FLT1—Signaling Pathways—VEGFA—brain cancer	4.68e-06	3.07e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—RELA—brain cancer	4.67e-06	3.06e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HES1—brain cancer	4.66e-06	3.06e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IRS2—brain cancer	4.65e-06	3.05e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—ERBB2—brain cancer	4.64e-06	3.05e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—STAT3—brain cancer	4.63e-06	3.04e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—RELA—brain cancer	4.63e-06	3.04e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—EGFR—brain cancer	4.62e-06	3.04e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—RELA—brain cancer	4.61e-06	3.03e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—ERBB2—brain cancer	4.6e-06	3.02e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—EGFR—brain cancer	4.59e-06	3.01e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—ERBB2—brain cancer	4.59e-06	3.01e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IRS2—brain cancer	4.57e-06	3e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HES1—brain cancer	4.56e-06	3e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NOTCH2—brain cancer	4.56e-06	3e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—ERBB2—brain cancer	4.55e-06	2.99e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—STAT3—brain cancer	4.55e-06	2.99e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—IDH1—brain cancer	4.49e-06	2.95e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—TP53—brain cancer	4.49e-06	2.95e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—ERBB2—brain cancer	4.47e-06	2.94e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—IL2—brain cancer	4.47e-06	2.94e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—IRS2—brain cancer	4.46e-06	2.93e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	4.46e-06	2.93e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PDGFRA—brain cancer	4.44e-06	2.91e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—BSG—brain cancer	4.43e-06	2.91e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—IL2—brain cancer	4.39e-06	2.88e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VAV1—brain cancer	4.35e-06	2.86e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PDGFRA—brain cancer	4.34e-06	2.85e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IRS2—brain cancer	4.33e-06	2.85e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ENO2—brain cancer	4.33e-06	2.84e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IRS2—brain cancer	4.32e-06	2.84e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—CTNNB1—brain cancer	4.32e-06	2.83e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—SPP1—brain cancer	4.31e-06	2.83e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—MYC—brain cancer	4.3e-06	2.83e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—ERBB2—brain cancer	4.24e-06	2.79e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—CTNNB1—brain cancer	4.24e-06	2.78e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—ERBB2—brain cancer	4.23e-06	2.78e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—SPP1—brain cancer	4.22e-06	2.77e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—EGFR—brain cancer	4.21e-06	2.76e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—IL2—brain cancer	4.2e-06	2.76e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	4.2e-06	2.76e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—STAT3—brain cancer	4.2e-06	2.76e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—RELA—brain cancer	4.17e-06	2.74e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL2—brain cancer	4.17e-06	2.74e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—RELA—brain cancer	4.16e-06	2.73e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL2—brain cancer	4.16e-06	2.73e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—ERBB2—brain cancer	4.15e-06	2.72e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—EGFR—brain cancer	4.13e-06	2.71e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—ERBB2—brain cancer	4.13e-06	2.71e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—APC—brain cancer	4.11e-06	2.7e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PIK3CG—brain cancer	4.11e-06	2.7e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—CCND1—brain cancer	4.1e-06	2.69e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—RELA—brain cancer	4.07e-06	2.67e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—RELA—brain cancer	4.07e-06	2.67e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—CTNNB1—brain cancer	4.06e-06	2.66e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—ERBB2—brain cancer	4.05e-06	2.66e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—ERBB2—brain cancer	4.04e-06	2.65e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—APC—brain cancer	4.03e-06	2.65e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PIK3CG—brain cancer	4.03e-06	2.65e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CTNNB1—brain cancer	4.02e-06	2.64e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP2C9—brain cancer	4.02e-06	2.64e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CTNNB1—brain cancer	4.01e-06	2.63e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—CTNNB1—brain cancer	3.98e-06	2.62e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—EGFR—brain cancer	3.95e-06	2.59e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—APC—brain cancer	3.94e-06	2.59e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—CTNNB1—brain cancer	3.91e-06	2.57e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—MYC—brain cancer	3.9e-06	2.56e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IRS2—brain cancer	3.9e-06	2.56e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—RELA—brain cancer	3.88e-06	2.55e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—ERBB2—brain cancer	3.85e-06	2.53e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PIK3CG—brain cancer	3.83e-06	2.51e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—APC—brain cancer	3.83e-06	2.51e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PIK3CG—brain cancer	3.82e-06	2.51e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—APC—brain cancer	3.82e-06	2.51e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—EGFR—brain cancer	3.81e-06	2.5e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—ERBB2—brain cancer	3.81e-06	2.5e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IRS2—brain cancer	3.81e-06	2.5e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—IDH1—brain cancer	3.81e-06	2.5e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—EGFR—brain cancer	3.79e-06	2.49e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PIK3CG—brain cancer	3.77e-06	2.48e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ENO2—brain cancer	3.77e-06	2.48e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—STAT3—brain cancer	3.76e-06	2.47e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL2—brain cancer	3.76e-06	2.47e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL2—brain cancer	3.74e-06	2.46e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HES1—brain cancer	3.74e-06	2.46e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—CTNNB1—brain cancer	3.71e-06	2.44e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—CTNNB1—brain cancer	3.7e-06	2.43e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—STAT3—brain cancer	3.69e-06	2.43e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—TP53—brain cancer	3.68e-06	2.42e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL2—brain cancer	3.67e-06	2.41e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CCND1—brain cancer	3.66e-06	2.4e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL2—brain cancer	3.66e-06	2.4e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CTNNB1—brain cancer	3.63e-06	2.38e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CTNNB1—brain cancer	3.61e-06	2.37e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—VEGFA—brain cancer	3.57e-06	2.35e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CCND1—brain cancer	3.57e-06	2.34e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PDGFRA—brain cancer	3.56e-06	2.34e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ENO2—brain cancer	3.55e-06	2.33e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—CTNNB1—brain cancer	3.54e-06	2.32e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—STAT3—brain cancer	3.54e-06	2.32e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CTNNB1—brain cancer	3.53e-06	2.32e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—TP53—brain cancer	3.53e-06	2.32e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—STAT3—brain cancer	3.51e-06	2.3e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—STAT3—brain cancer	3.5e-06	2.3e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL2—brain cancer	3.49e-06	2.29e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—STAT3—brain cancer	3.47e-06	2.28e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SPP1—brain cancer	3.46e-06	2.27e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PIK3CG—brain cancer	3.45e-06	2.27e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PIK3CG—brain cancer	3.44e-06	2.26e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—APC—brain cancer	3.44e-06	2.26e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—EGFR—brain cancer	3.42e-06	2.25e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—BSG—brain cancer	3.42e-06	2.24e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—STAT3—brain cancer	3.41e-06	2.24e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CCND1—brain cancer	3.4e-06	2.24e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CTNNB1—brain cancer	3.37e-06	2.21e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PIK3CG—brain cancer	3.37e-06	2.21e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—APC—brain cancer	3.37e-06	2.21e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—EGFR—brain cancer	3.36e-06	2.21e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—CTNNB1—brain cancer	3.34e-06	2.19e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—RELA—brain cancer	3.34e-06	2.19e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—ERBB2—brain cancer	3.32e-06	2.18e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—MYC—brain cancer	3.29e-06	2.16e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—STAT3—brain cancer	3.24e-06	2.13e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—STAT3—brain cancer	3.23e-06	2.12e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—MYC—brain cancer	3.23e-06	2.12e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—EGFR—brain cancer	3.21e-06	2.11e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—RELA—brain cancer	3.21e-06	2.11e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PIK3CG—brain cancer	3.2e-06	2.1e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—VEGFA—brain cancer	3.19e-06	2.1e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—ERBB2—brain cancer	3.19e-06	2.09e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—EGFR—brain cancer	3.19e-06	2.09e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—EGFR—brain cancer	3.18e-06	2.09e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—MYC—brain cancer	3.17e-06	2.08e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—STAT3—brain cancer	3.16e-06	2.08e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—EGFR—brain cancer	3.16e-06	2.07e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—RELA—brain cancer	3.15e-06	2.07e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—STAT3—brain cancer	3.15e-06	2.07e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—ERBB2—brain cancer	3.13e-06	2.06e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IRS2—brain cancer	3.13e-06	2.05e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—VEGFA—brain cancer	3.11e-06	2.04e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—EGFR—brain cancer	3.1e-06	2.04e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	3.1e-06	2.04e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—STAT3—brain cancer	3.08e-06	2.03e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—STAT3—brain cancer	3.08e-06	2.02e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—ERBB2—brain cancer	3.06e-06	2.01e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ENO2—brain cancer	3.01e-06	1.98e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—MYC—brain cancer	3.01e-06	1.98e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL2—brain cancer	3e-06	1.97e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—MYC—brain cancer	3e-06	1.97e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—RELA—brain cancer	2.99e-06	1.96e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—RELA—brain cancer	2.98e-06	1.96e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—ERBB2—brain cancer	2.97e-06	1.95e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—VEGFA—brain cancer	2.97e-06	1.95e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—ERBB2—brain cancer	2.96e-06	1.95e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—EGFR—brain cancer	2.94e-06	1.93e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—STAT3—brain cancer	2.94e-06	1.93e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—IDH1—brain cancer	2.94e-06	1.93e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MYC—brain cancer	2.94e-06	1.93e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—EGFR—brain cancer	2.93e-06	1.93e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—STAT3—brain cancer	2.91e-06	1.91e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CTNNB1—brain cancer	2.9e-06	1.9e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL2—brain cancer	2.89e-06	1.9e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—EGFR—brain cancer	2.87e-06	1.89e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—EGFR—brain cancer	2.86e-06	1.88e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MYC—brain cancer	2.86e-06	1.88e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL2—brain cancer	2.84e-06	1.86e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CCND1—brain cancer	2.82e-06	1.85e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—EGFR—brain cancer	2.8e-06	1.84e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—EGFR—brain cancer	2.8e-06	1.84e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CTNNB1—brain cancer	2.79e-06	1.83e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CCND1—brain cancer	2.77e-06	1.82e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—APC—brain cancer	2.76e-06	1.81e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CG—brain cancer	2.76e-06	1.81e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CTNNB1—brain cancer	2.74e-06	1.8e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MYC—brain cancer	2.73e-06	1.79e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MYC—brain cancer	2.7e-06	1.78e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—brain cancer	2.7e-06	1.77e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL2—brain cancer	2.69e-06	1.77e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—RELA—brain cancer	2.69e-06	1.77e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL2—brain cancer	2.69e-06	1.76e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—CTNNB1—brain cancer	2.68e-06	1.76e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—EGFR—brain cancer	2.67e-06	1.75e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ERBB2—brain cancer	2.67e-06	1.75e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—EGFR—brain cancer	2.64e-06	1.74e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—RELA—brain cancer	2.63e-06	1.73e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CCND1—brain cancer	2.63e-06	1.72e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CCND1—brain cancer	2.62e-06	1.72e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ERBB2—brain cancer	2.62e-06	1.72e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CTNNB1—brain cancer	2.6e-06	1.71e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CTNNB1—brain cancer	2.59e-06	1.7e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—STAT3—brain cancer	2.53e-06	1.66e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—VEGFA—brain cancer	2.46e-06	1.61e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—STAT3—brain cancer	2.43e-06	1.6e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL2—brain cancer	2.42e-06	1.59e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—VEGFA—brain cancer	2.41e-06	1.58e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—brain cancer	2.41e-06	1.58e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—STAT3—brain cancer	2.39e-06	1.57e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL2—brain cancer	2.37e-06	1.56e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCND1—brain cancer	2.36e-06	1.55e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—brain cancer	2.35e-06	1.54e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CTNNB1—brain cancer	2.34e-06	1.53e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—STAT3—brain cancer	2.33e-06	1.53e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ENO2—brain cancer	2.32e-06	1.53e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCND1—brain cancer	2.31e-06	1.52e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—EGFR—brain cancer	2.3e-06	1.51e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—brain cancer	2.29e-06	1.5e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CTNNB1—brain cancer	2.29e-06	1.5e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—brain cancer	2.28e-06	1.5e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—STAT3—brain cancer	2.27e-06	1.49e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—STAT3—brain cancer	2.26e-06	1.48e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MYC—brain cancer	2.26e-06	1.48e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—brain cancer	2.24e-06	1.47e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MYC—brain cancer	2.22e-06	1.46e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EGFR—brain cancer	2.21e-06	1.45e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EGFR—brain cancer	2.17e-06	1.43e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MYC—brain cancer	2.17e-06	1.42e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—RELA—brain cancer	2.16e-06	1.42e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ERBB2—brain cancer	2.14e-06	1.41e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—EGFR—brain cancer	2.12e-06	1.39e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MYC—brain cancer	2.11e-06	1.38e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MYC—brain cancer	2.1e-06	1.38e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EGFR—brain cancer	2.06e-06	1.35e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—brain cancer	2.06e-06	1.35e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EGFR—brain cancer	2.06e-06	1.35e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—STAT3—brain cancer	2.04e-06	1.34e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—brain cancer	2.01e-06	1.32e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—STAT3—brain cancer	1.99e-06	1.31e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CG—brain cancer	1.98e-06	1.3e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL2—brain cancer	1.94e-06	1.28e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCND1—brain cancer	1.89e-06	1.24e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MYC—brain cancer	1.89e-06	1.24e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CTNNB1—brain cancer	1.88e-06	1.23e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—brain cancer	1.86e-06	1.22e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MYC—brain cancer	1.85e-06	1.22e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EGFR—brain cancer	1.85e-06	1.22e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—brain cancer	1.82e-06	1.2e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EGFR—brain cancer	1.81e-06	1.19e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—brain cancer	1.73e-06	1.14e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CG—brain cancer	1.73e-06	1.14e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—brain cancer	1.73e-06	1.13e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—brain cancer	1.65e-06	1.08e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—STAT3—brain cancer	1.63e-06	1.07e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CG—brain cancer	1.63e-06	1.07e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—brain cancer	1.55e-06	1.02e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—brain cancer	1.52e-06	9.99e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MYC—brain cancer	1.52e-06	9.98e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EGFR—brain cancer	1.49e-06	9.76e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CG—brain cancer	1.38e-06	9.07e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—brain cancer	1.25e-06	8.19e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CG—brain cancer	1.07e-06	7e-06	CbGpPWpGaD
